NCT02824575 - Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 27, 2021

Study Completion Date

December 27, 2021

Conditions

Breast CancerBreast AdenocarcinomaHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastRecurrent Breast CarcinomaStage IV Breast Cancer

Interventions

DRUG

Rebastinib

50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

DRUG

Paclitaxel

Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

DRUG

Eribulin Mesylate

Eribulin 1.4 mg/m2 day 1 \& 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

Trial Locations (1)

Montefiore Medical Center, The Bronx